Drug intelligence / Profile preview

enshuangping

Development stage: Preclinical
Modality: Small Molecules

Overview

Enshuangping is a drug studied in China for its effects on glucose and lipid metabolism in obese patients with type 2 diabetes mellitus. The available information suggests it is being evaluated as a potential therapy for metabolic disorders, specifically targeting both glycemic control and lipid profiles in this patient population. Detailed mechanism of action, chemical class, or international approval status are not specified in the available sources.

Brand names: enshuangping
Other names: enshuangping

Beyond the preview

Go deeper on enshuangping.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on enshuangping.

Explore the full profile